{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T00:19:14Z","timestamp":1787530754663,"version":"build-2736575974"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T00:00:00Z","timestamp":1781481600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T00:00:00Z","timestamp":1787529600000},"content-version":"vor","delay-in-days":70,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Colorectal Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>To investigate whether colorectal cancer (CRC) sidedness is associated with intraoperative lavage cytology results, tumor recurrence, and prognosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>Using data from a multicenter prospective observational study conducted by the Japanese Society for Cancer of the Colon and Rectum (JSCCR), we retrospectively analyzed prognosis and recurrence patterns in pathological stage II\/III right-sided and left-sided CRC, stratified by positive versus negative lavage cytology results.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 1500 patients met the inclusion criteria and were enrolled. Of these, 534 had right-sided CRC and 966 had left-sided CRC. Fifty-nine patients (3.9%) had positive lavage cytology. Among patients with recurrence, pT4, positive lavage cytology, and right-sided tumor location were independently associated with peritoneal recurrence.<\/jats:p>\n                    <jats:p>\n                      Among cytology-negative patients, the 5-year relapse-free survival (RFS) rate was significantly higher in right-sided than in left-sided CRC (79.6% vs. 73.4%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.01), whereas the 5-year overall survival (OS) rate did not differ significantly (89.2% vs. 87.7%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.52). Among cytology-positive patients, no statistically significant differences in RFS or OS were observed between tumor locations. However, among cytology-positive patients who developed recurrence, post-recurrence survival was significantly worse in right-sided CRC than in left-sided CRC (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.04).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Among cytology-negative patients, left-sided CRC was associated with poorer RFS than right-sided CRC, although OS did not differ. Right-sided tumor location and positive lavage cytology were independently associated with peritoneal recurrence among patients who developed recurrence. Among cytology-positive patients, right-sided CRC was associated with poorer post-recurrence survival.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00384-026-05173-z","type":"journal-article","created":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T16:55:18Z","timestamp":1781542518000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Evaluation of the prognostic impact of intraoperative cytology results according to tumor sidedness in stage II\/III resectable colorectal cancer"],"prefix":"10.1007","volume":"41","author":[{"given":"Akihiro","family":"Usui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotoshi","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenjiro","family":"Kotake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kotaro","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Shuto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayasu","family":"Kawasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Komori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heita","family":"Ozawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chihiro","family":"Kosugi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Ohue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimihiko","family":"Funahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ichiro","family":"Takemasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideyuki","family":"Ishida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinsuke","family":"Kazama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshifumi","family":"Shimada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hajime","family":"Motohashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Kinugasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukihide","family":"Kanemitsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Ochiai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soichiro","family":"Ishihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michio","family":"Itabashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Sugihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Ueno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,15]]},"reference":[{"key":"5173_CR1","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1159\/000543921","volume":"106","author":"T Matsuda","year":"2025","unstructured":"Matsuda T, Fujimoto A, Igarashi Y (2025) Colorectal cancer: epidemiology, risk factors, and public health strategies. Digestion 106:91\u201399. https:\/\/doi.org\/10.1159\/000543921","journal-title":"Digestion"},{"key":"5173_CR2","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A (2024) Cancer statistics, 2024. CA Cancer J Clin 74:12\u201349. https:\/\/doi.org\/10.3322\/caac.21820","journal-title":"CA Cancer J Clin"},{"key":"5173_CR3","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/PL00012102","volume":"6","author":"T Muto","year":"2001","unstructured":"Muto T, Kotake K, Koyama Y (2001) Colorectal cancer statistics in Japan: data from JSCCR registration, 1974\u20131993. Int J Clin Oncol 6:171\u2013176. https:\/\/doi.org\/10.1007\/PL00012102","journal-title":"Int J Clin Oncol"},{"key":"5173_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10147-019-01485-z","volume":"25","author":"Y Hashiguchi","year":"2020","unstructured":"Hashiguchi Y, Muro K, Saito Yea et al (2020) Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer. Int J Clin Oncol 25:1\u201342. https:\/\/doi.org\/10.1007\/s10147-019-01485-z","journal-title":"Int J Clin Oncol"},{"issue":"13","key":"5173_CR5","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1016\/S1470-2045(13)70490-X","volume":"2045","author":"Y Yamada","year":"2013","unstructured":"Yamada Y, Takahari D, Matsumoto Hea et al (2013) Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial. Lancet Oncol 2045(13):1278\u20131286. https:\/\/doi.org\/10.1016\/S1470-2045(13)70490-X","journal-title":"Lancet Oncol"},{"key":"5173_CR6","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1093\/annonc\/mdw206","volume":"27","author":"K Yamazaki","year":"2016","unstructured":"Yamazaki K, Nagase M, Tamagawa Hea et al (2016) Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G). Ann Oncol 27:1539\u20131546. https:\/\/doi.org\/10.1093\/annonc\/mdw206","journal-title":"Ann Oncol"},{"key":"5173_CR7","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1056\/nejmoa1403108","volume":"371","author":"F Loupakis","year":"2014","unstructured":"Loupakis F, Cremolini C, Masi Gea et al (2014) Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. N Engl J Med 371:1609\u20131618. https:\/\/doi.org\/10.1056\/nejmoa1403108","journal-title":"N Engl J Med"},{"key":"5173_CR8","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1001\/jama.2023.4428","volume":"329","author":"J Watanabe","year":"2023","unstructured":"Watanabe J, Muro K, Shitara K et al (2023) Panitumumab vs bevacizumab added to standard first-line chemotherapy and overall survival among patients with RAS wild-type, left-sided metastatic colorectal cancer: a randomized clinical trial. JAMA 329:1271\u20131282. https:\/\/doi.org\/10.1001\/jama.2023.4428","journal-title":"JAMA"},{"key":"5173_CR9","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1097\/DCR.0000000000000412","volume":"58","author":"P Quere","year":"2015","unstructured":"Quere P, Facy O, Manfredi Sea et al (2015) Epidemiology, management, and survival of peritoneal carcinomatosis from colorectal cancer. Dis Colon Rectum 58:743\u2013752. https:\/\/doi.org\/10.1097\/DCR.0000000000000412","journal-title":"Dis Colon Rectum"},{"key":"5173_CR10","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1016\/j.ejso.2013.10.001","volume":"40","author":"YRBM Van Gestel","year":"2014","unstructured":"Van Gestel YRBM, Thomassen I, Lemmens Vea et al (2014) Metachronous peritoneal carcinomatosis after curative treatment of colorectal cancer. Eur J Surg Oncol 40:963\u2013969. https:\/\/doi.org\/10.1016\/j.ejso.2013.10.001","journal-title":"Eur J Surg Oncol"},{"key":"5173_CR11","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1002\/ijc.10635","volume":"101","author":"B Iacopetta","year":"2002","unstructured":"Iacopetta B (2002) Are there two sides to colorectal cancer? Int J Cancer 101:403\u2013408","journal-title":"Int J Cancer"},{"key":"5173_CR12","doi-asserted-by":"publisher","first-page":"157","DOI":"10.5114\/aoms.2016.58596","volume":"13","author":"M Mik","year":"2017","unstructured":"Mik M, Berut M, Dziki L et al (2017) Right-and left-sided colon cancer-clinical and pathological differences of the disease entity in one organ. Arch Med Sci 13:157\u2013162. https:\/\/doi.org\/10.5114\/aoms.2016.58596","journal-title":"Arch Med Sci"},{"issue":"1","key":"5173_CR13","doi-asserted-by":"publisher","first-page":"e104","DOI":"10.1016\/j.clcc.2018.10.005","volume":"18","author":"L Yaqi","year":"2019","unstructured":"Yaqi L, Yang F, Weixing D, Qingguo L, Sanjun C, Peng J (2019) Prognostic effect of tumor sidedness in colorectal cancer: a SEER-based analysis. Clin Colorectal Cancer 18(1):e104\u2013e116. https:\/\/doi.org\/10.1016\/j.clcc.2018.10.005","journal-title":"Clin Colorectal Cancer"},{"key":"5173_CR14","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1016\/j.ejca.2015.03.015","volume":"51","author":"SY Brul\u00e9","year":"2015","unstructured":"Brul\u00e9 SY, Jonker DJ, Karapetis CS et al (2015) Location of colon cancer (right-sided versus left-sided) as a prognostic factor and a predictor of benefit from cetuximab in NCIC CO.17. Eur J Cancer 51:1405\u20131414. https:\/\/doi.org\/10.1016\/j.ejca.2015.03.015","journal-title":"Eur J Cancer"},{"key":"5173_CR15","doi-asserted-by":"publisher","DOI":"10.3390\/jpm13071114","author":"S Waldstein","year":"2023","unstructured":"Waldstein S, Spengler M, Pinchuk IV, Yee NS (2023) Impact of colorectal cancer sidedness and location on therapy and clinical outcomes: role of blood-based biopsy for personalized treatment. J Pers Med. https:\/\/doi.org\/10.3390\/jpm13071114","journal-title":"J Pers Med"},{"key":"5173_CR16","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1002\/ags3.12825","volume":"8","author":"H Kobayashi","year":"2024","unstructured":"Kobayashi H, Kotake K, Maeda K et al (2024) Peritoneal lavage cytology in patients with curative resection for stage II and III colorectal cancer: a multi-institutional prospective study. Ann Gastroenterol Surg 8:807\u2013816. https:\/\/doi.org\/10.1002\/ags3.12825","journal-title":"Ann Gastroenterol Surg"},{"key":"5173_CR17","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1016\/S1470-2045(20)30527-1","volume":"21","author":"T Andr\u00e9","year":"2020","unstructured":"Andr\u00e9 T, Meyerhardt J, Iveson T et al (2020) Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA collaboration): final results from a prospective, pooled analysis of six randomised, phase 3 trials. Lancet Oncol 21:1620\u20131629. https:\/\/doi.org\/10.1016\/S1470-2045(20)30527-1","journal-title":"Lancet Oncol"},{"key":"5173_CR18","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1200\/JCO.2010.33.6297","volume":"29","author":"DG Haller","year":"2011","unstructured":"Haller DG, Tabernero J, Maroun Jea et al (2011) Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. J Clin Oncol 29:1465\u20131471. https:\/\/doi.org\/10.1200\/JCO.2010.33.6297","journal-title":"J Clin Oncol"},{"key":"5173_CR19","doi-asserted-by":"publisher","first-page":"2198","DOI":"10.1200\/JCO.2006.08.2974","volume":"25","author":"JP Kuebler","year":"2007","unstructured":"Kuebler JP, Wieand HS, O\u2019Connell MJ et al (2007) Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol 25:2198\u20132204. https:\/\/doi.org\/10.1200\/JCO.2006.08.2974","journal-title":"J Clin Oncol"},{"issue":"1","key":"5173_CR20","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1186\/s12885-022-09267-z","volume":"22","author":"S Sadahiro","year":"2022","unstructured":"Sadahiro S, Sakamoto K, Tsuchiya T, Sakamoto J et al (2022) Prospective observational study of the efficacy of oral uracil and tegafur plus leucovorin for stage II colon cancer with risk factors for recurrence using propensity score matching (JFMC46\u20131201). BMC Cancer 22(1):170. https:\/\/doi.org\/10.1186\/s12885-022-09267-z","journal-title":"BMC Cancer"}],"container-title":["International Journal of Colorectal Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00384-026-05173-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00384-026-05173-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00384-026-05173-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T23:29:49Z","timestamp":1787527789000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00384-026-05173-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,15]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5173"],"URL":"https:\/\/doi.org\/10.1007\/s00384-026-05173-z","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-9047848\/v1","asserted-by":"object"}]},"ISSN":["1432-1262"],"issn-type":[{"value":"1432-1262","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,15]]},"assertion":[{"value":"6 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"140"}}